EGFR and colorectal carcinoma: In this study, we found that ErbB3/EGFR activated in CRC gefitinib-resistant cell lines (Fig. 7A), suggesting multi-targeted therapy of EGFR and ErbB3 could solve the TKI-resistance issue.